Research programme: chitosan-encapsulated dermatology therapeutics - Advancell
Alternative Names: ANs29; ANs30; ANs31Latest Information Update: 16 Jul 2016
At a glance
- Originator Advancell
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acne; Psoriasis; Rosacea; Wounds
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acne in Spain
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psoriasis in Spain
- 16 Jul 2016 No recent reports of development identified for preclinical development in Rosacea in Spain